Modern pharmaceutical company assured this Tuesday that its budding vaccine for the prevention of COVID-19, mRNA-1273, “can generate neutralizing antibodies in the elderly and adults greater than levels comparable to [los que genera en] young adults “, as suggested by provisional data published in the journal The New England Journal of Medicine.
“These interim Phase 1 data suggest that mRNA-1273, our candidate to become a vaccine for the prevention of COVID-19, can generate neutralizing antibodies in older adults and the elderly at levels comparable to those of younger adults “, said Tal Zaks, MD, Ph. D., Moderna’s medical director, quoted in the note.
Last July the US pharmaceutical company announced the start of phase 3 of the trials of its experimental vaccine against the disease of COVID-19 for the general population and that includes the participation of 30,000 volunteers; and its CEO, Stephen Bancel, said in the middle of the month that they could find out if their vaccine is effective in October, although he considered that it is most likely that those expected data on the final phase of its development will arrive in November.
“Given the increased morbidity and mortality of COVID-19 in older adults and the elderly, these data they give us optimism by demonstrating the protection of mRNA-1273 in this population, “added Zaks.
Moderna explains that this interim analysis evaluated a Phase 1 vaccination program that includes the inoculation of two doses of mRNA-123, which were administered 28 days apart. 40 patients divided into two groups, one between the ages of 56 and 70 and the other over 71 years of age.
Some volunteers were administered doses of 25 micrograms (µg) and others 100 µg. The analyzes carried out one month after the administration of the second dose revealed that with the doses of 100 µg, higher neutralizing antibody titers.
The pharmacist emphasizes that, in general, both doses were well tolerated and did not generate serious side effects.
Moderna cited headaches, myalgia, chills and pain at the injection site as the most common, “most of which were from mild to moderate intensity and of limited duration “.
However, he points out that after the second vaccination “there were two serious systemic adverse events “: fever in a participant in the group aged 56 to 70 years who received the 25 µg dose and fatigue in a participant in the group older than 70 years, who received the 100 µg dose.
Although Moderna pointed out that they did not “reveal no pattern of concern. “